Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher
Merck (MRK) reported Q3 2026 earnings of $2.49 per share, beating estimates, and raised its 2026 EPS guidance to $2.77-$2.82. Revenue was $18.09B, also beating expectations. Keytruda sales grew 6% to $8.6B. Eli Lilly (LLY) and Johnson & Johnson (JNJ) also saw stock gains. MRK is up 43% YTD, LLY 29%, and JNJ 35%.
How this was made
The 30-second read
Why it matters
Merck’s Q3 beat and explicit 2026 EPS guidance raise are the clearest catalyst, while Eli Lilly’s raised revenue guidance supports obesity-franchise expectations. J&J’s move is described more as peer correlation than a disclosed catalyst.
Market read
Traders can use the guidance raises to update near-term earnings expectations for MRK and LLY, while monitoring Merck’s stated 2027 transition risks.
What to watch
The article flags margin compression at Merck (operating margin down) and vaccine hesitancy/pricing pressure as potential headwinds, which could reduce the durability of the post-earnings optimism.
Background
The article frames Merck as a Keytruda-anchored growth story versus Eli Lilly’s obesity-driven surge, with J&J positioned as diversified via MedTech.
Ticker impact
Merck reported Q3 2026 results with adjusted EPS and revenue beats and raised 2026 adjusted EPS guidance to $2.77-$2.82.
Likely near-term support as traders reprice 2026 earnings power, with caution into 2027 due to stated generic competition pressures.
The article includes specific beat metrics and a concrete guidance increase, plus explicit forward headwinds (2027 generic competition) that can drive two-sided positioning.
Eli Lilly is described as climbing after its own beat, with full-year revenue guidance raised to $91B-$92B driven by Mounjaro and Zepbound.
Likely continued upward pressure as the market prices in higher 2026 revenue expectations from obesity franchise strength.
The piece attributes the move to a guidance raise and product drivers, but provides fewer granular financial details than for Merck.
Johnson & Johnson is noted as edging higher alongside peers, with the article framing diversification via its MedTech arm.
Likely modest follow-through at most, since no JNJ-specific earnings or guidance numbers are provided here.
JNJ is mentioned with a small price gain and general diversification context, but the article does not disclose a JNJ-specific new datapoint.
Market effects
Reinforces positive read-through for large-cap pharma earnings quality, especially oncology and obesity franchises, while highlighting looming patent/generic transition risk.
US large-cap healthcare sentiment likely improves as investors rotate within pharma based on guidance revisions.
Limited direct global spillover beyond multinational pharma sentiment and pipeline/generic-transition expectations.
Counterpoint
Merck’s raised 2026 outlook may be offset by 2027 generic competition pressures, so the market could fade the rally once investors focus on the transition timeline.
Key entities
- companyMerck
Q3 2026 results beat and raised 2026 adjusted EPS guidance; Keytruda and Winrevair strength; 2027 generic competition risk highlighted.
- companyEli Lilly
Described as rising on its own beat and raised full-year revenue guidance driven by Mounjaro and Zepbound.
- companyJohnson & Johnson
Edging higher in the peer group; diversification via MedTech mentioned without new JNJ-specific financial datapoints.
